22
Participants
Start Date
October 1, 2017
Primary Completion Date
April 6, 2021
Study Completion Date
April 6, 2022
OBP-301
"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
Pembrolizumab
200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
National Cancer Center Hospital East, Kashiwa
Collaborators (1)
Oncolys BioPharma Inc
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Toshihiko Doi
OTHER